About the Company
Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late-stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off- the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PSTI News
Pluri Inc. Announces 1-for-8 Reverse Share Split
HAIFA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the “Company"), a leading biotechnology company that transforms ...
Pluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences
Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, today announced ...
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method
About Pluri Inc. Pluri™ is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well ...
Pluri Inc. announces breakthrough in immune cell therapy production
HAIFA, Israel - Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR), a biotechnology firm, has been granted a U.S. patent for a novel method of expanding immune cells, which could significantly impact the cell ...
Pluri Inc. to enact 1-for-8 reverse stock split on April 1
HAIFA, Israel - Biotechnology firm Pluri Inc. (NASDAQ: PLUR) (TASE: PLUR), known for its cell-based technology solutions, has announced a reverse share split of its common shares at a ratio of 1-for-8 ...
Pluri CEO Issues Shareholder Update
Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its ...
Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences
HAIFA, Israel, March 28, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote ...
Pluri Inc. Announces 1-for-8 Reverse Share Split
HAIFA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the “Company"), a leading biotechnology company that transforms cells into solutions, today ...
Pluri Inc. Announces 1-for-8 Reverse Share Split
Zeit Aktuelle Nachrichten 12:12 Pluri to implement a 1-for-8 reverse stock split 12:06 Pluri Inc. Announces 1-for-8 Reverse Share Split HAIFA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- Pluri Inc ...
Loading the latest forecasts...